Linking To And Excerpting From StatPearls’ “Postmenopausal Bleeding”

Today, I review, link to, and excerpt from StatPearls‘ “Postmenopausl Bleeding”.

All that follows is from the above resource.

• Continuing Education Activity
• Introduction
• Etiology
• Epidemiology
• Pathophysiology
• Histopathology
• History and Physical
• Evaluation
• Treatment / Management
• Differential Diagnosis
• Prognosis
• Complications
• Consultations
• Deterrence and Patient Education
• Enhancing Healthcare Team Outcomes
• Review Questions
• References

Introduction

Menopause is characterized by the complete absence of menstrual cycles, which occurs when a female has no ovarian follicles left in reserve and is clinically diagnosed when a woman has had amenorrhea for 1 year. In the United States, the average age of menopause is 51.[1] Bleeding after menopause has been established, termed postmenopausal bleeding (PMB), is considered abnormal and is the reason for approximately two-thirds of all gynecologic office visits in postmenopausal women.[2][3]

The differential diagnoses associated with PMB include several conditions. Though the most common cause of PMB is atrophy of the lower reproductive tract, 90% of postmenopausal women diagnosed with endometrial cancer presented with vaginal bleeding.[4][5] As with most malignancies, early diagnosis and management lead to a significantly more favorable prognosis.[6] Therefore, any postmenopausal woman with vaginal bleeding should be promptly and appropriately evaluated through a comprehensive clinical examination and diagnostic studies, including endometrial biopsy and imaging. Typically, management depends on the etiology identified. Due to the frequency with which clinicians encounter PMB, healthcare professionals should have enhanced knowledge in selecting appropriate diagnostic tests, managing the etiology, and fostering effective interprofessional teamwork to improve outcomes in patients with this common condition.

Etiology

PMB is often attributed to the uterus, with women mistakenly attributing bleeding to menstrual bleeding despite not having had menses for over 1 year. However, the bleeding may also arise from the urethra, vulva, vagina, cervix, or rectum. The most common cause of PMB is genitourinary atrophy, accounting for 60%.[7] The etiology of PMB may also be nongynecologic (eg, the urethra, bladder, or GI tract) and mistaken for vaginal bleeding.[1] Some common underlying causes of PMB include:

• Vaginal or endometrial atrophy
• Urogenital infections (eg, endometrial tuberculosis, vaginitis, cystitis, or cervicitis)
• Medications (eg, estrogen, tamoxifen, and anticoagulants)
• Uterine leiomyomas
• Genital tract malignancies
• Vaginal foreign bodies
• Endometrial polyps
• Genitourinary atrophy
• Endometrial hyperplasia with or without atypia [1][8][4][5]

Epidemiology

Vaginal bleeding is reported in up to 10% of postmenopausal women and is the presenting symptom for approximately two-thirds of gynecologic office visits in this population.[9][2] However, the incidence of PMB may decrease with age. With the onset of menopause, bleeding is reported in approximately 40% of women per year, but 3 years after menopause, PMB decreases to 4% per year.[1]

In the United States, the incidence of endometrial cancer has risen gradually, increasing by about 1% to 2% each year. By 2022, the annual rate of uterine cancer reached 28.8 cases per 100,000 women, up from 23.5 per 100,000 in 2000. Mortality has also trended upward, with an overall death rate of 5.3 per 100,000 women annually between 2019 and 2023, compared with 4.1 per 100,000 in 2000.[10]

Endometrial cancer is the fifth most common cause of death due to malignancy in the United States and the fourth most common overall cancer in females.[11] Furthermore, endometrial cancer is the most commonly diagnosed cancer in women and the most common site of uterine cancer, accounting for 92% of cases.[5][12] Over 90% of postmenopausal women with endometrial cancer present with PMB.[5] In women younger than 50, less than 1% of PMB is secondary to endometrial cancer. However, the incidence of PMB due to endometrial cancer increases to 24% in women older than 80.[13] The global incidence of endometrial cancer is increasing, primarily due to the increased prevalence of endometrial cancer risk factors (eg, obesity and late menopause). The number of patients diagnosed with endometrial cancer is anticipated to double by the year 2030.[2][14]

Pathophysiology

The most common etiology for PMB is an atrophic endometrium. The hypoestrogenic environment following menopause leads to genitourinary atrophy. The collapsed and atrophic endometrial lining within the uterus contains scant or no fluid to prevent friction within the cavity, leading to epithelial microerosions and subsequent chronic inflammation. Chronic endometritis secondary to atrophy can present with vaginal spotting or light bleeding. Pelvic ultrasounds performed in these patients typically reveal a thin endometrial stripe with an otherwise normal appearance, a small uterus, and small ovaries.[15]

Conversely, unopposed estrogen exposure often develops premalignant or malignant endometrial conditions. Systemic estrogen-only therapy, obesity, and estrogen-secreting tumors can lead to abnormal endometrial changes. Some women have genetic predispositions to endometrial cancer, eg, Lynch syndrome and Cowden disease.[12] More recent studies demonstrate that BRCA gene mutation carriers may have a slightly increased risk of endometrial cancer, especially those with a BRCA1 mutation.[16]

Histopathology

Postmenopausal Endometrial Histologic Findings

The hypoestrogenic environment has several effects on the postmenopausal endometrium that are apparent on microscopic examination. Normal premenopausal proliferative endometrium contains regularly spaced, ordered glands lined by simple epithelial cells within the stroma with an approximate 1 to 1 gland-to-stroma ratio. Furthermore, histologically, mitotic activity is a characteristic feature of proliferative endometrium. Conversely, normal histologic findings in the postmenopausal endometrium show widely spaced glands that vary from small to cystically dilated. Moreover, the mitotic proliferative activity characteristic of a premenopausal endometrium is not apparent in postmenopausal endometrial cells.[8][4] Pathologic endometrial findings have varying histologic features depending on the underlying etiology. For instance, the histopathology of endometrial polyps frequently shows cellular immaturity with cystic hyperplasia, while smooth muscle fibers are a characteristic finding of uterine fibroids. Both conditions have a higher risk of malignant transformation in postmenopausal women.[17][18] In women with PMB, the most concerning abnormal histologic findings are endometrial hyperplasia and carcinoma.

Endometrial Hyperplasia Histologic Findings

Characteristic histologic findings of endometrial hyperplasia include widespread crowding of endometrial glands, a disordered proliferation of glands, and an increased gland-to-stroma ratio. The precise ratio diagnostic of endometrial hyperplasia is debated; however, many pathologists use a gland-to-stroma ratio of 2 to 1.[4] In benign endometrial hyperplasia, glandular cytology is normal, with only occasional mitotic figures noted. However, on histological examination, gland crowding and abnormal gland nuclei are typically seen in endometrial intraepithelial neoplasia (EIN), considered a premalignant condition.[8][4]

Endometrial Cancer Histologic Findings

One of the most concerning etiologies of PMB is endometrial cancer, which is typically subclassified into type I or II based on histologic morphology, grade, and hormone receptors.[14][19] The following histologic findings are associated with each enodmetial cancer type:

• Endometrial carcinoma type 1: The most common histologic type of endometrial carcinoma, accounting for up to 90% of uterine cancers, is primarily composed of grade I or II endometrioid adenocarcinomas, which involve the endometrial glands. Histologically, solid areas, maze-like glands, or appreciable cribriforming are observed. Most of these endometrioid adenocarcinomas are low-grade and confined to the uterus.[11]

• Endometrial carcinoma type 2: These are rare, high-grade, poorly differentiated, and more aggressive types of uterine cancers that include clear cell carcinoma, sarcoma, carcinosarcoma, and papillary serous histologies. Type 2 endometrial cancers have a higher risk of extrauterine disease at diagnosis and a worse prognosis than type I tumors. For instance, though only 10% of uterine cancers are papillary serous, they cause approximately 40% of deaths.[11]

Physical Exam

On physical exam, it is crucial to thoroughly evaluate the internal and external anatomy of the genital tract. A speculum exam should be performed to visualize bleeding sites, genital lesions, lacerations, urethral prolapse, and signs of genitourinary atrophy, which typically include pale, dry vaginal epithelium with loss of rugae. Erythema, petechiae, friability, and discharge may indicate inflammation. Furthermore, clinicians can palpate for pelvic masses, abdominal distention, and enlarged lymph nodes through a bimanual exam.[14][21][6]

Evaluation

Diagnostic Studies

In addition to the clinical assessment, diagnostic evaluation of PMB is primarily directed toward excluding endometrial hyperplasia or malignancy. In April 2026, the American College of Obstetricians and Gynecologists (ACOG) published a new guideline on the use of endometrial biopsy and transvaginal ultrasound for the evaluation of PMB. This Clinical Practice Update revises prior recommendations in light of the increasing incidence of endometrial cancer, along with newer evidence regarding tumor subtypes, associated risk factors, and ongoing challenges in delivering gynecologic care. For most patients presenting with postmenopausal bleeding, initial evaluation should include both transvaginal ultrasonography and endometrial sampling.[10]